FOXO Technologies Inc. (NYSE American: FOXO) is a multi-segment healthcare and life science services company that operates a critical access hospital, behavioral health treatment facilities, and a biospecimen sourcing business. Revenue comes from three segments: Healthcare, which includes patient services at Myrtle Recovery Centers and Scott County Community Health (operating as Big South Fork Medical Center, a 25-bed Critical Access Hospital in Oneida, Tennessee); Life Science Services, which generates transactional revenue from the sale of bio-samples and bulk biological materials to biotechnology, clinical research, and pharmaceutical research customers through Vector BioSource Inc., acquired September 19, 2025; and Labs, which earns royalty income from Illumina, Inc. related to sales of the Infinium Mouse Methylation Array. Originally formed in April 2020 as a special purpose acquisition company under the name Delwinds Insurance Acquisition Corp., FOXO assembled its current operations through acquisitions completed between June 2024 and September 2025. As of December 31, 2025, the company carried approximately 2.5 billion common shares outstanding and over 281 billion potentially dilutive preferred shares, reflecting a heavily diluted capital structure.

Revenue model

Healthcare segment: fee-for-service patient billings reimbursed by Medicare, Medicaid, and commercial payers. Life Science Services segment: transactional product sales of bio-samples and biological materials, with payment terms of 30 to 60 days per ASC 606. Labs segment: royalty payments from Illumina, Inc. on sales of the Infinium Mouse Methylation Array.

Products and services

Big South Fork Medical Center (BSF): 25-bed Critical Access Hospital in Oneida, Tennessee, operating since August 2017 under RCHI. Myrtle Recovery Centers: residential detoxification and residential rehabilitation for up to 30 patients, licensed by the Tennessee Department of Mental Health and Substance Abuse Services, commenced operations August 14, 2023; Nonresidential Office-Based Opiate Treatment (OBOT) facility commenced November 1, 2023. Vector BioSource Inc.: biospecimen sourcing and distribution of high-quality bio-samples and bulk biological materials for life science research. Labs: epigenetic biomarker technology; royalty stream from Illumina Infinium Mouse Methylation Array.

Customers and end markets

Healthcare: patients in rural east Tennessee covered by Medicare, Medicaid, and commercial insurers. Life Science Services: biotechnology, clinical research, and pharmaceutical research companies purchasing bio-samples and biological materials. Labs: licensees including Illumina, Inc.

Value-chain role

In Healthcare, direct provider of acute care hospital services and substance use disorder treatment. In Life Science Services, sourcing and distribution intermediary supplying biospecimens to research-stage customers, relying on specimen providers and third-party logistics providers. In Labs, IP licensor earning royalties on third-party product sales.

Geographic exposure

Primary operations in Oneida, Tennessee (hospital and behavioral health facilities). Regional healthcare office in Farragut, Tennessee. Life science services office in Stoughton, Massachusetts. Corporate office in West Palm Beach, Florida. Vector conducts international sourcing activities per the FY2025 10-K risk factors.

Source: SEC 10-K, filed 2026-04-15

Industry: Services-Commercial Physical & Biological Research Peers: Ton Strategy Co BTCS Inc LOGIQ, INC. CRISP MOMENTUM INC. GSE SYSTEMS INC MARIN SOFTWARE INC Qumu Corp